Castle Creek Biosciences

Executive Summary

Castle Creek Biosciences is a late-stage private biotechnology company pioneering transformative cell and gene therapies for rare genetic diseases, with an initial focus on skin and connective tissue disorders. Its proprietary autologous fibroblast platform enables personalized, re-dosable treatments. The lead candidate, D-Fi, is currently in a registrational Phase 3 trial for dystrophic epidermolysis bullosa (DEB), a devastating blistering disease with no approved therapies. The company's approach addresses the underlying genetic cause, offering the potential for durable clinical benefit. Castle Creek's platform versatility also supports a pipeline of additional indications, positioning it as a leader in fibroblast-based gene therapy. With strong preclinical and clinical data, the company is nearing a pivotal milestone that could transform the treatment landscape for DEB patients.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 D-Fi topline data readout for DEB75% success
• Q2 2027Potential BLA submission for D-Fi65% success
• H2 2026Initiation of Phase 1/2 trial for second indication (e.g., recessive DEB or another connective tissue disorder)60% success